Every sponsor wants the same thing at the end of a clinical program: a submission that reviewers can open, understand, and act on quickly. Often the biggest obstacle is not the science, but the data. Datasets built with inconsistent structures, naming conventions, and terminology slow review, trigger information requests, and can put a submission’s timeline at risk.
Data standardization is one of the most practical ways to prevent that.
Here is how it works and why it matters.
What we mean by data standardization
In clinical research, standardization means collecting, organizing, and presenting study data in a consistent, predefined structure that regulators and sponsors recognize. The key components are:
- CDASH (Clinical Data Acquisition Standards Harmonization): Standard conventions for how data is captured on case report forms from the start of a study.
- SDTM (Study Data Tabulation Model): A standard structure for organizing collected data into domains such as demographics, adverse events, and laboratory results.
- ADaM (Analysis Data Model): A standard for analysis-ready datasets, with clear traceability back to the source data.
- Define-XML: The metadata file that documents every dataset, variable, and derivation so reviewers can see how the data was built.
- Controlled terminology and coding dictionaries: Standard vocabularies, including CDISC controlled terminology, MedDRA for adverse events, and WHODrug for medications, so the same concept is always described the same way.
Why regulators care
Under the FDA’s study data standards requirements, standardized electronic study data is expected for NDAs, ANDAs, and BLAs, and for commercial INDs. Submissions that don’t conform to the FDA’s published standards and technical specifications can face delays or, in serious cases, a refusal to file. Other regulators, including Japan’s PMDA, have similar expectations.
The reason is practical. Reviewers evaluate many submissions, and standardized data lets them use consistent tools and review approaches across programs. When every submission follows the same structure, reviewers spend less time working out how the data is organized and more time evaluating safety and efficacy.
Four ways standardization speeds up review
1. Fewer questions about the data.
When datasets follow recognized models and are documented in Define-XML, reviewers can trace results to their source without asking the sponsor to explain the structure. Fewer information requests mean fewer back-and-forth cycles.
2. Faster use of automated review tools.
Standardized data can be loaded into regulatory review and analysis tools with minimal preparation. Non-standard data usually requires manual handling, which takes time.
3. Earlier detection of quality issues.
Validation checks, such as those run with tools like Pinnacle 21, flag structural and conformance problems against regulatory rules. Running these checks throughout a study, rather than only before submission, means issues are fixed while they’re still small, not discovered when the clock is running.
4. Cleaner, more traceable results.
Standard structures make the path from raw data to tabulations to analysis datasets to tables, listings, and figures easier to follow. That traceability supports confidence in the results and makes any follow-up questions easier to answer.
Where standardization pays off most: planning early
The biggest mistake typically seen across the industry comes from treating standardization as a conversion exercise at the end of a study. Converting messy data after the fact is slower, more expensive, and more error-prone than building in standards from the start.
A better approach is to plan for standards before the first participant is enrolled:
- Design CRFs with CDASH in mind, so collected data maps cleanly to SDTM.
- Define mapping specifications and controlled terminology up front, not after database lock.
- Validate continuously, with conformance checks throughout the study rather than a single pass at the end.
- Align on the data standards expectations of the relevant regulatory agency early, including the version of the standards and the technical conformance guide in effect.
- Keep documentation current, including the Study Data Reviewer’s Guide and Define-XML, so they reflect the final data, not an earlier draft.
The bigger picture
Standardization reduces rework, shortens the path to a complete submission, and gives sponsors more predictable timelines. It also makes data reusable, so that pooled analyses, future studies, and lifecycle submissions don’t have to start from scratch.
For sponsors working with a contract research partner, it is worth asking early on: How are standards built into study design? When is validation performed? How is traceability maintained from CRF to submission?
Partner with Axis Clinicals US
At AXIS Clinicals US, we approach data management and biostatistics with the submission in mind from day one. If you are planning a study and want to talk about how standards can be built into your program, we would welcome the conversation.
Contact our team to discuss your next study.
Make sure you check out this article https://www.washingtonguardian.com/business/what-cros-overlook-when-recruiting-for-long-in-house-stays/ that AXIS was featured in to read more on this topic.